Thaiprayoon, Apisitt
Chantarasorn, Yodpong
Oonanant, Worrapoj
Kasorn, Anongnard
Longsompurana, Phoomintara
Tapaneeyakorn, Satita
Riangrungroj, Pinpunya
Loison, Fabien
Kruse, Andrew C.
DeLisa, Matthew P.
Waraho-Zhmayev, Dujduan
Funding for this research was provided by:
National Research Council of Thailand (NRCT5-RGJ63006)
National Research Council of Thailand (Fiscal year 2024)
National Research Council of Thailand (Fiscal year 2024)
National Research Council of Thailand (Fiscal year 2024)
National Research Council of Thailand (Fiscal year 2024)
National Research Council of Thailand (Fiscal year 2024)
Navamindradhiraj University Research Fund (03/2563)
Navamindradhiraj University Research Fund (03/2563)
Navamindradhiraj University Research Fund (03/2563)
Asahi Glass Foundation
Thailand Science Research and Innovation (FRB670016/0164)
Article History
Received: 30 May 2024
Accepted: 23 January 2025
First Online: 28 January 2025
Declarations
:
: M.P.D. has financial interests in Gauntlet, Inc., Glycobia, Inc., Resilience, Inc., UbiquiTX, Inc., and Versatope Therapeutics, Inc. M.P.D.‘s interests are reviewed and managed by Cornell University in accordance with their conflict-of-interest policies. All other authors declare no competing interests. A.C.K. is a cofounder and consultant for biotechnology companies Tectonic Therapeutic and Seismic Therapeutic, and also for the Institute for Protein Innovation, a nonprofit research institute. The other authors do not have any Competing-Interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
: The study was approved by the Institutional Biosafety Committee of King Mongkut’s University of Technology (IBC-2020-031 and IBC-2023-004).